Pieris Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Reverse Merger (Tables)

12 Months Ended

Dec. 31, 2024

The following table summarizes the fair value of identifiable assets acquired and liabilities assumed as part of the recapitalization (in thousands):


	As of
	December 13, 2024
Assets
Current assets:
Cash	$	13,781
Accounts receivable		377
Prepaid expenses and other current assets		595
Total current assets		14,753
Total assets	$	14,753

Liabilities
Current liabilities:
Accounts payable	$	142
Accrued expenses and other current liabilities		3,000
Total current liabilities		3,142
Total liabilities	$	3,142

Net assets acquired	$	11,611